How much does Yervoy cost, and what drives the price?
The price of Yervoy (ipilimumab) is usually discussed in terms of the drug’s list price and the total treatment cost based on the dosing schedule. Yervoy is a prescription cancer immunotherapy given by intravenous infusion, and the final out-of-pocket and billed totals depend on factors like dose size (tied to body weight), number of infusions, infusion-site fees, insurance coverage, and patient assistance programs.
Because pricing changes over time and varies by country and payer, the cleanest way to compare “cost” across treatments is to compare:
1) list prices per dose (or per vial), and
2) typical total number of infusions and dosing regimens for the same cancer setting.
What counts as “similar treatments” to compare against Yervoy?
People most often compare Yervoy with other immune checkpoint therapies used in similar cancers and lines of therapy, such as:
- Opdivo (nivolumab) and Keytruda (pembrolizumab) from the PD-1 class
- Tecentriq (atezolizumab) and Imfinzi (durvalumab) (PD-L1 class)
- Other CTLA-4 or combination regimens when used alongside PD-1/PD-L1 drugs
Cost comparisons also depend on whether you’re comparing:
- Yervoy alone vs a PD-1/PD-L1 drug alone, or
- Yervoy used in combination (often higher total cost because you’re paying for two drugs), versus a single-drug regimen.
How does Yervoy’s cost typically compare to PD-1/PD-L1 drugs?
In many real-world billing comparisons, PD-1/PD-L1 therapies are priced differently from CTLA-4 therapies, so the “cheapest” option depends on the specific regimen and dosing schedule. When Yervoy is used in combination with a PD-1/PD-L1 drug, the total regimen cost generally increases because both drugs are billed.
A practical rule for comparisons is:
- Yervoy + a PD-1/PD-L1 drug costs more than either drug alone.
- A single-agent PD-1/PD-L1 regimen may have a lower total drug cost than a CTLA-4–containing combination, even if the per-dose prices are similar.
Does the cancer type and regimen change the cost comparison a lot?
Yes. The number of doses, cycle length, and whether you’re using combination therapy can swing the total treatment cost significantly. Even if two drugs are both “immune checkpoint inhibitors,” their dosing schedules can differ by:
- Cancer indication (e.g., melanoma vs lung cancer)
- Disease stage (adjuvant vs metastatic)
- Treatment line (first-line vs later)
So Yervoy’s cost relative to alternatives is best evaluated per indication and regimen, not as a single global comparison.
What should patients look at when comparing costs (billed vs out-of-pocket)?
Patients typically want to compare more than list price. Key differences:
- Insurance coverage tiers and prior authorization requirements
- Copay assistance or manufacturer support programs
- Deductibles and coinsurance structure
- Infusion center billing (administration and facility fees), which can be a meaningful part of the total
- Treatment duration (some regimens use fixed cycles; others can continue until progression)
Two patients can see very different out-of-pocket costs for the same regimen depending on insurance and where infusions are given.
Are there biosimilars or cheaper alternatives that can undercut Yervoy?
For older biologic drugs, biosimilars can reduce costs, but for immune checkpoint inhibitors, biosimilar availability depends on the specific molecule and country. If biosimilars exist for a comparable PD-1/PD-L1 drug in your region, that could change the “cost” ranking versus Yervoy. In contrast, Yervoy’s relative cost may stay higher or lower depending on whether the comparator has a biosimilar option and how payers price it.
If you tell me the cancer and regimen, I can narrow the comparison
To make a truly useful cost comparison, I need:
- Cancer type (and stage if known)
- Whether Yervoy is being used alone or with another drug
- The comparator you’re considering (e.g., Opdivo vs Keytruda vs Opdivo+Yervoy)
- Your country (pricing is region-specific)
- Whether you want list price comparison or estimated out-of-pocket
If you share those details, I can explain how the total regimen cost typically stacks up across the closest alternatives.
Sources
No sources were provided in the prompt, so I can’t cite specific price figures or comparisons.